How children and caregivers viewed the change from nusinersen to risdiplam for treating spinal muscular atrophy.
作者信息
Agosto Caterina, Benedetti Francesca, Salamon Eleonora, Mercante Anna, Papa Simonetta, Giacomelli Luca, Santini Anna, Benini Franca
机构信息
Pediatric Pain and Palliative Care Service, Department of Women's and Children's Health, Padua University Hospital, Padua, Italy.
Pediatric Residency Program, University of Padua, Padua, Italy.
出版信息
Acta Paediatr. 2023 Feb;112(2):311-312. doi: 10.1111/apa.16568. Epub 2022 Oct 18.
PMID:36222023
Abstract
摘要
相似文献
1
How children and caregivers viewed the change from nusinersen to risdiplam for treating spinal muscular atrophy.
Acta Paediatr. 2023 Feb;112(2):311-312. doi: 10.1111/apa.16568. Epub 2022 Oct 18.
2
A case series evaluating patient perceptions after switching from nusinersen to risdiplam for spinal muscular atrophy.
Muscle Nerve. 2024 Feb;69(2):179-184. doi: 10.1002/mus.28015. Epub 2023 Dec 1.
3
Cost-Effectiveness of Technologies for the Treatment of Spinal Muscular Atrophy: A Systematic Review of Economic Studies.
Value Health Reg Issues. 2024 Jul;42:100985. doi: 10.1016/j.vhri.2024.02.002. Epub 2024 Apr 26.
4
Nusinersen treatment of older children and adults with spinal muscular atrophy.
Neuromuscul Disord. 2021 Mar;31(3):183-193. doi: 10.1016/j.nmd.2020.12.006. Epub 2020 Dec 20.
5
Early experiences of nusinersen for the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers.
Muscle Nerve. 2021 Mar;63(3):311-319. doi: 10.1002/mus.27116. Epub 2020 Dec 19.
6
How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.
J Comp Eff Res. 2022 Apr;11(5):347-370. doi: 10.2217/cer-2021-0216. Epub 2022 Jan 18.
7
Nusinersen helps restore walking ability in childhood spinal muscular atrophy.
Pediatr Int. 2019 Jul;61(7):728-729. doi: 10.1111/ped.13867. Epub 2019 Jul 9.
8
[Nusinersen in the treatment of spinal muscular atrophy].
Ideggyogy Sz. 2018 Mar 30;71(3-04):90-94. doi: 10.18071/isz.71.0090.
9
Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study.
Lancet Child Adolesc Health. 2021 Jul;5(7):491-500. doi: 10.1016/S2352-4642(21)00100-0. Epub 2021 Jun 3.
10
Children and young adults with spinal muscular atrophy treated with nusinersen.
Eur J Paediatr Neurol. 2021 Jan;30:1-8. doi: 10.1016/j.ejpn.2020.11.004. Epub 2020 Dec 4.
引用本文的文献
1
Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians.
Drugs. 2024 Jul;84(7):747-762. doi: 10.1007/s40265-024-02051-2. Epub 2024 Jun 15.
2
Switching from Nusinersen to Risdiplam: A Croatian Real-World Experience on Effectiveness and Safety.
J Pers Med. 2024 Feb 24;14(3):244. doi: 10.3390/jpm14030244.
3
Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment.
Int J Mol Sci. 2023 Jul 26;24(15):11939. doi: 10.3390/ijms241511939.
Zotero 插件